Skip to main content
EN
  1. Learn the basics
  2. Find stocks
  3. Understand a stock

ALNYLAM PHARMACEUTICALS, INC.

ALNY United States NASDAQ
Last Close: Market Cap: Currency: USD Reports in: Sector: Health Care Industry:

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

In short

Loading the key numbers…

What the sector means for this company

These sentences describe the numbers; they are not a recommendation. This content is not investment advice.

Price chart: each candle shows one day's opening, highest, lowest and closing price. The projection line is our model's estimate - a model, not a promise.

Price chart

Daily candles · prices in USD

View
Layers
From
To

Key statistics: the most used ratios in one place. Tap the icon next to a name for a short explanation. Compare them with similar companies, not with the whole market.

Financial statements: the income statement shows sales and profit, the balance sheet what the company owns and owes, and the cash flow statement the money that actually came in and went out. How to read them.

Company policy and leadership: an AI-assisted assessment of how the company sells, executes, uses its resources and treats people, production and service. Read it as a starting point for your own research.

News: the latest articles about the company, grouped by day. Each has ratings for the outlet's stance towards the company and how factual it is. What the ratings mean.